Date: 2012-01-05
Type of information: Joint-venture agreement
Compound:
Company: Midatech (UK) MonoSol Rx (USA)
Therapeutic area: Metabolic diseases
Type agreement: joint-venture
licensing
commercialisation
Action mechanism:
Disease: diabetes
Details: MonoSol Rx, the developer of PharmFilm® drug delivery technology, and Midatech Ltd., the developer of MidaForm™ nanoparticle excipients and a global leader and center of excellence for the design, development, synthesis and manufacture of nanomedicines, have launched their strategic joint venture, MidaSol Therapeutics LP.
The launch will focus on the commercialization, via partnering or licensing, of products that have combined the IP of the companies’ respective technologies in the primary treatment of diabetes. The companies announced recently that they are conducting a Phase I clinical study of their most advanced candidate which utilizes insulin-passivated gold glyconanoparticles (MidaForm™ insulin) formulated into PharmFilm® for buccal delivery (http://biopharmanalyses.fr/clinical-trails/?pageid=495). Results of the Phase I study are expected in the first half of 2012.
MidaSol Therapeutics non-injectable Insulin addresses the longstanding unmet need for millions of diabetics who are dependent on insulin injections by providing a more convenient, non-invasive, treatment option. Insulin, stabilized on a nanoparticle and delivered transbuccally has the potential to offer diabetic patients a viable alternative to injectable insulin.
Pipeline products for commercialization include MidaForm™ GLP-1 formulated in PharmFilm® and a unique mixed MidaForm™ nanoparticle containing therapeutic levels of both insulin and GLP-1 on the same nanoparticle.
Financial terms:
Latest news:
